This study reports the outcomes of dogs with grade 3 mast cell tumors (MCTs). Clinical and histopathological data were available for 43 dogs. Median progression-free survival (PFS) and overall survival (OS) were 133 and 257 days, respectively.
Introduction
A grading system described by Patnaik is currently used to classify cutaneous mast cell tumors (MCTs) based on histomorphologic features. Grade 3 tumors are the most poorly differentiated and invasive of the MCTs. 1 Grade 3 tumors account for 29%-40% of all canine MCTs and the reported metastatic rate of this subset of tumors ranges from 55% to 96%. [1] [2] [3] [4] Early reports evaluating patients with grade 3 MCTs treated with surgery alone showed these patients to have a poor long-term prognosis. 1, 5, 6 More recent literature has shown variable improvement in survival times for dogs diagnosed with high-grade MCTs. 7, 8 One study found that patients with grade 3 tumors treated with prednisone and vinblastine (VBL) had a median survival of 331 days. With only a small number of dogs in the published study treated in the adjuvant setting, it is difficult to compare the reported median survival time to studies where larger populations of dogs were treated with chemotherapy following complete surgical excision. 9 Evaluation of a larger number of dogs with grade 3 MCTs treated with prednisone and VBL in the adjuvant setting reported a median survival of 1,374 days, and a 1 yr survival probability of 0.71 was reached for yet another group of dogs with grade 3 tumors treated with prednisone and VBL in the adjuvant setting. 10, 11 A protocol consisting of VBL, cyclophosphamide, and prednisone (VCP) was recently evaluated and dogs with grade 3
MCTs were reported to have a median survival of 145 days. Again, few of these dogs were treated in the adjuvant setting. 12 Several studies have shown a considerable degree of interobserver variation between pathologists when grading MCTs. 13 Assessment of tumor proliferation markers such as Ki-67, agyrophilic nucleolar organizer regions (AgNORs), and mitotic index (MI) have all been evaluated in canine MCTs for prognostic significance. MCTs with a Ki-67 index of 23, defined as the number of positive cells/grid area, were significantly associated with an increased incidence of recurrence and tumor-related mortality. 14 The MI, defined as the number of mitotic figures/10 high-power fields (HPFs), has also been shown to be a predictor of overall survival (OS). One report showed significantly prolonged survival in dogs with grade 3 MCTs with a MI #5 and median survival was not reached. In contrast, median survival time was ,2 mo for those with a MI .5.
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Also shown to be associated with outcome in canine MCTs was the location of KIT, a tyrosine kinase receptor important for mast cell proliferation and differentiation. 16, 17 Tumors that have abnormal cytoplasmic KIT protein localization (staining patterns 2 and 3)
have been reported to carry a worse prognosis than tumors with normal perimembrane protein localization (staining pattern 1).
18,19
The purpose of this retrospective study was to evaluate the outcomes and prognostic characteristics of a large group of dogs with grade 3 MCTs. Outcome Assessment 
Materials and Methods

Patient Selection and Evaluation
Immunohistochemical Staining and Evaluation
Immunohistochemical staining and evaluation for Ki-67 and KIT were performed according to methods previously described. 14, 18 Immunostaining for Ki-67 was performed with the Benchmark staining platform a and KIT immunostaining was performed using a Dako Autostainer b .
AgNOR Histochemical Staining and Evaluation
AgNOR histochemical staining was performed using a previously described modified silver staining technique. 22 To determine the average AgNOR count/cell in each tumor, AgNORs were counted in 100 random mast cells throughout the tumor (at the original magnification 31,000).
Mitotic Index Evaluation
A single pathologist evaluated tissue sections stained with hematoxylin and eosin via light microscopy and determined the number of mitotic figures. The area of the tumor sample with the highest amount of mitotic activity was evaluated.
Statistical Analysis
Curves for PFS and OS were calculated using the Kaplan-Meier because of low sample size. Statistical significance was set at P,0.05. All data were analyzed using SAS c statistical software.
Results
Forty-three dogs met the inclusion criteria. Twenty-five were spayed females, 10 were castrated males, and 8 were intact males.
Mean body weight was 28 kg (range, 2.9-50.5 kg) and mean age was 9 yr (range, 2-13 yr). Tumor characteristics and treatment information have been summarized in Table 1 
Outcome
Seventeen patients were censored from analysis. Nine of these dogs were still alive, three dogs died of reasons unrelated to their tumor, and five dogs were lost to follow-up. The PFS and OS for the entire population were 133 days and 257 days, respectively ( Figure 1) . 
Mast Cell Tumors in Dogs
Prognostic factors that were predictors of outcome for the entire population of dogs (n¼43) in univariate analysis were described in Table 1 . A subgroup analysis of dogs with ALC (n¼35) was also performed and the univariate analysis results were presented in Table 2 .
In the univariate analysis, tumor size, LN status, and MI were significantly associated with PFS in the entire population of dogs.
In the multivariate analysis, tumor size, and LN status were significantly associated with PFS (P¼0.02 and P¼0.04, respectively).
In the univariate analysis, LN status, ALC, LN treatment, and MI were significantly associated with OS in the entire population. In the multivariate analysis, only LN status remained prognostic (P¼0.04).
For all dogs with ALC, tumor size and MI were significantly associated with PFS in the univariate analysis. For dogs with ALC, LN status, LN treatment, and MI were significantly associated with OS in the univariate analysis (Figures 2 and 3 ).
Tumor Progression
Tumor progression for all dogs was presented in Table 3 . and ALC developed local recurrence. Twenty-four out of 27 of the dogs that failed due to local recurrence and/or regional metastasis 
FIGURE 1 Kaplan-Meier curve depicting progression-free survival (PFS) and overall survival (OS) for all dogs (n¼43).
Discussion
Treatment of the primary tumor in this group of dogs affected outcome. Dogs that had ALC experienced significantly longer survival times versus those that did not, which is not unexpected.
Contrary to some of the earlier reports supporting a poor prognosis for dogs with high-grade tumors, these results confirm that definitive local control is worthwhile and can improve outcome.
It should be noted that local control was not significant when evaluated with multivariate analysis. The fact that so few dogs died due to distant metastatic disease also suggests that even though all dogs were not initially completely staged, few actually had distant metastasis at the time of diagnosis.
Consequently, under-staging is not likely to be an issue. Regarding the outcome (i.e., cause of death), it is possible that some of the dogs that failed due to locoregional recurrence might have had subclinical distant metastasis; however, the direct cause of death or euthanasia was secondary to the locoregional disease and the as- Evaluation of MI is an inexpensive, readily available prognostic tool that should be used for evaluation of patients with grade 3 MCTs.
Staining patterns for Ki-67 and AgNORs were not prognostic for survival; however, the proliferation markers were elevated for most tumors that were evaluated. Furthermore, KIT staining patterns 2 and 3 were observed in all, except one, of the examined tumors. These results support the high-grade nature of tumors included in this study.
Limitations of this study include the nonstandardization of treatment and the relatively small number of dogs included in the study and subgroup analysis.
Conclusion
In conclusion, results of this retrospective study indicate that some 
